Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 17 January 2013 | By Alexander Gaffney, RAC,
The European Commission (EC) has launched a public consultation on four revised chapters of its good manufacturing practice guidelines, saying a number of changes were necessary to reflect best practices and the latest thinking.
One of the sections set to be revised is GMP Chapter 3, which details ways in which companies should reduce the potential for cross-contamination in facilities that manufacture multiple product lines. Factories should be designed properly to ensure that cross-contamination does not occur, and owners are advised to follow Quality Risk Management principles to assess and controls risks present or inherent in the facility.
"Risk assessment should include among other parameters a toxicological evaluation of the products being manufactured," the chapter notes.
Some facilities, however, will not be permitted to manufacture multiple product lines. Those include cases when cross-contamination cannot be adequately controlled by operational or technical measures, when or if scientific data does not support threshold values, or if threshold values are too difficult to detect.
Chapter 5 expands upon this logic, and EC notes the two should be read in conjunction with a draft European Medicines Agency (EMA) guideline on exposure limits in manufacturing facilities. The chapter contains several new revisions, including refined guidance on where products should and should not be manufactured (i.e. not in the presence of non-medical products) and the use of technical poisons like pesticides or herbicides (don't use them in the presence of medical products).
Sections 26, 27 and 28 of the chapter also explain that suppliers and starting materials will need to be qualified so as to ensure that products are traceable within the supply chain. This will require documentation and supervision to guard against adulteration.
"The supporting evidence for each supplier/material approval should be maintained," EC explained. "Staff involved in these activities should have a current knowledge of the suppliers, the supply chain and the associated risks involved. Where possible, starting materials should be purchased directly from the manufacturer of the starting material."
This logic applies not just to active pharmaceutical ingredients (APIs), but also to excipients which could "pose a particular risk to the quality of the medicinal product," the chapter explains. All starting materials used in the production of medicines should be tested, as should the finished product.
Chapter 6 includes a new section on technical transfer of testing methods as well, which explains that test methods should be verified so that they are the same as those validated in the original marketing authorization dossier. The transfer of this technology between testing facilities needs to be documented and tested to ensure that the technology is the same, operators are adequately trained, standards are maintained and acceptance criteria is established.
Finally, GMP Chapter 8 has undergone revisions to reflect new Quality Risk Management principles for the investigation of defects, complaints and responsibilities. The Chapter is extensive, and includes everything from detailing the receipt of the complaint, its investigation, its analysis, determining its causes, determining how to prevent such defects in the future, and an assessment of recall actions.
All chapters will go into effect on 17 June 2013.
Tags: European Commission, GMP
Regulatory Focus newsletters
All the biggest regulatory news and happenings.